|
US5824311A
(en)
|
1987-11-30 |
1998-10-20 |
Trustees Of The University Of Pennsylvania |
Treatment of tumors with monoclonal antibodies against oncogene antigens
|
|
US4870287A
(en)
|
1988-03-03 |
1989-09-26 |
Loma Linda University Medical Center |
Multi-station proton beam therapy system
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5846945A
(en)
|
1993-02-16 |
1998-12-08 |
Onyx Pharmaceuticals, Inc. |
Cytopathic viruses for therapy and prophylaxis of neoplasia
|
|
US5801005A
(en)
|
1993-03-17 |
1998-09-01 |
University Of Washington |
Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
|
|
JPH08506247A
(ja)
|
1993-07-09 |
1996-07-09 |
アムジェン ボールダー インコーポレイテッド |
組換えctla4ポリペプチドおよびその製造方法
|
|
GB9506466D0
(en)
|
1994-08-26 |
1995-05-17 |
Prolifix Ltd |
Cell cycle regulated repressor and dna element
|
|
US6451995B1
(en)
|
1996-03-20 |
2002-09-17 |
Sloan-Kettering Institute For Cancer Research |
Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
|
|
US5760395A
(en)
|
1996-04-18 |
1998-06-02 |
Universities Research Assoc., Inc. |
Method and apparatus for laser-controlled proton beam radiology
|
|
US5739169A
(en)
|
1996-05-31 |
1998-04-14 |
Procept, Incorporated |
Aromatic compounds for inhibiting immune response
|
|
US5844905A
(en)
|
1996-07-09 |
1998-12-01 |
International Business Machines Corporation |
Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
|
|
EP0970128A1
(en)
|
1997-03-21 |
2000-01-12 |
Brigham And Women's Hospital |
Immunotherapeutic ctla-4 binding peptides
|
|
BR9907691B1
(pt)
|
1998-02-05 |
2011-05-31 |
|
derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
|
|
WO2000014257A1
(en)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Fusion receptors specific for prostate-specific membrane antigen and uses thereof
|
|
AU2472400A
(en)
|
1998-10-20 |
2000-05-08 |
City Of Hope |
CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
|
|
ES2706547T3
(es)
|
1998-12-23 |
2019-03-29 |
Pfizer |
Anticuerpos monoclonales humanos para CTLA-4
|
|
DK1187629T3
(da)
|
1999-04-19 |
2005-01-17 |
Glaxosmithkline Biolog Sa |
Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
NZ517202A
(en)
|
1999-08-24 |
2004-05-28 |
Medarex Inc |
Human CTLA-4 antibodies and their uses
|
|
CA2410510A1
(en)
|
2000-06-02 |
2001-12-13 |
Memorial Sloan-Kettering Cancer Center |
Artificial antigen presenting cells and methods of use thereof
|
|
US7446179B2
(en)
|
2000-11-07 |
2008-11-04 |
City Of Hope |
CD19-specific chimeric T cell receptor
|
|
CN101016543A
(zh)
*
|
2000-11-17 |
2007-08-15 |
罗切斯特大学 |
筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
DK2348119T3
(en)
*
|
2002-02-01 |
2017-08-21 |
Oxford Biomedica (Uk) Ltd |
Polycistronic lentiviral vector
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
JP4733635B2
(ja)
|
2003-07-31 |
2011-07-27 |
イミューノメディクス、インコーポレイテッド |
抗cd19抗体
|
|
EP1765846A4
(en)
|
2004-07-13 |
2010-02-17 |
Cell Genesys Inc |
AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
US8389282B2
(en)
|
2007-03-30 |
2013-03-05 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
|
PT2242773T
(pt)
|
2008-02-11 |
2017-09-15 |
Cure Tech Ltd |
Anticorpos monoclonais para o tratamento de tumores
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
|
WO2010014784A2
(en)
|
2008-08-01 |
2010-02-04 |
Bristol-Myers Squibb Company |
Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
EP3053932B1
(en)
|
2010-02-19 |
2020-07-22 |
Xencor, Inc. |
Novel ctla4-ig immunoadhesins
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012129514A1
(en)
|
2011-03-23 |
2012-09-27 |
Fred Hutchinson Cancer Research Center |
Method and compositions for cellular immunotherapy
|
|
US20130071414A1
(en)
*
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
|
WO2013071154A1
(en)
|
2011-11-11 |
2013-05-16 |
Fred Hutchinson Cancer Research Center |
Cyclin a1-targeted t-cell immunotherapy for cancer
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
WO2013126726A1
(en)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Double transgenic t cells comprising a car and a tcr and their methods of use
|
|
NZ702108A
(en)
|
2012-05-03 |
2016-09-30 |
Hutchinson Fred Cancer Res |
Enhanced affinity t cell receptors and methods for making the same
|
|
JP2014022858A
(ja)
|
2012-07-17 |
2014-02-03 |
Murata Mfg Co Ltd |
電力増幅器
|
|
LT2884999T
(lt)
|
2012-08-20 |
2021-04-12 |
Fred Hutchinson Cancer Research Center |
Ląstelinės imunoterapijos būdas ir kompozicijos
|
|
RU2729401C2
(ru)
|
2012-10-02 |
2020-08-06 |
Мемориал Слоан-Кеттеринг Кэнсер Сентер |
Композиции и способы для иммунотерапии
|
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
|
CN105682683A
(zh)
|
2013-08-02 |
2016-06-15 |
阿杜罗生物科技控股有限公司 |
结合cd27激动剂以及免疫检查点抑制以用于免疫刺激
|
|
SMT202300039T1
(it)
|
2013-09-13 |
2023-03-17 |
Beigene Switzerland Gmbh |
Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
|
|
CA2935951A1
(en)
*
|
2014-01-08 |
2015-07-16 |
1Globe Biomedical Co., Ltd. |
Novel synthetic biology-based adcc technology
|
|
CN122399016A
(zh)
*
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
CN106456670B
(zh)
*
|
2014-04-25 |
2020-01-07 |
蓝鸟生物公司 |
制备过继性细胞疗法的改善方法
|
|
RS63601B1
(sr)
*
|
2014-10-09 |
2022-10-31 |
Univ Yamaguchi |
Vektor ekspresije car i t ćelije koje eksprimiraju car
|
|
US10046047B2
(en)
*
|
2015-02-06 |
2018-08-14 |
Heat Biologics, Inc. |
Vector co-expressing vaccine and costimulatory molecules
|
|
PL3280729T3
(pl)
*
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
WO2016168595A1
(en)
*
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
CN107849102B
(zh)
*
|
2015-05-15 |
2022-05-13 |
希望之城 |
嵌合抗原受体组合物
|
|
WO2016197108A1
(en)
*
|
2015-06-05 |
2016-12-08 |
Board Of Regents, The University Of Texas System |
Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
|
|
TWI833684B
(zh)
*
|
2015-06-25 |
2024-03-01 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體(car)、組合物及其使用方法
|
|
MX2018004721A
(es)
*
|
2015-10-23 |
2018-07-06 |
Eureka Therapeutics Inc |
Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
|
|
BR112018014585A2
(pt)
*
|
2016-01-21 |
2018-12-11 |
Pfizer |
receptores de antígeno quiméricos que direcionam o receptor do fator de crescimento epidérmico variante iii
|
|
CN106279438B
(zh)
*
|
2016-08-24 |
2019-10-22 |
北京领柯生物科技有限公司 |
新型嵌合抗原受体及其用途
|
|
BR112019019941B1
(pt)
*
|
2017-03-27 |
2023-12-05 |
Noile-Immune Biotech, Inc |
Polinucleotídeo compreendendo uma sequência de base que codifica o receptor de antígeno quimérico, vetor e método
|
|
EP3625346A1
(en)
*
|
2017-05-16 |
2020-03-25 |
Cairn Biosciences, Inc. |
Multiplex assay
|
|
TW201908335A
(zh)
*
|
2017-07-25 |
2019-03-01 |
美國德州系統大學評議委員會 |
增強之嵌合抗原受體及其用途
|
|
US20210106667A1
(en)
*
|
2018-05-03 |
2021-04-15 |
Duke University |
Vaccine compositions and methods for enhanced antigen-specific vaccination
|
|
EP3743513A4
(en)
*
|
2018-11-06 |
2021-11-24 |
Nantkwest, Inc. |
NK-92 CELLS MODIFIED BY CHIMERIC ANTIGEN RECEPTOR
|